New Three-in-One Blood Test for Prostate Cancer
News Jun 20, 2017 | Original story from The Institute of Cancer Research
Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.
By testing cancer DNA in the bloodstream, researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with exciting new drugs called PARP inhibitors.
They also used the test to analyse DNA in the blood after treatment had started, so people who were not responding could be identified and switched to alternative therapy in as little as four to eight weeks.
And finally, they used the test to monitor a patient’s blood throughout treatment, quickly picking up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.
First test of its kind
The researchers, at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tumours.
It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.
The study is published in the prestigious journal Cancer Discovery. It was funded by the Prostate Cancer Foundation, Prostate Cancer UK, The Movember Foundation, Cancer Research UK and the National Institute for Health Research (NIHR) via the Experimental Cancer Medicine Centre Network, and the NIHR Biomedical Research Centre at The Royal Marsden and the ICR.
The test could help to extend or save lives, by targeting treatment more effectively, while also reducing the side-effects of treatment and ensuring patients don’t receive drugs that are unlikely to do them any good.
Resistance mutations identified
The new study is also the first to identify which genetic mutations prostate cancers use to resist treatment with olaparib. The test could potentially be adapted to monitor treatment with PARP inhibitors for other cancers.
Researchers at the ICR and The Royal Marsden collected blood samples from 49 men at The Royal Marsden with advanced prostate cancer enrolled in the TOPARP-A phase II clinical trial of olaparib.
Olaparib is good at killing cancer cells that have errors in genes that have a role in repairing damaged DNA such as BRCA1 or BRCA2. Some patients respond to the drug for years, but in other patients, the treatment either fails early, or the cancer evolves resistance.
Douglas Baker, aged 73 from Berkshire, has been receiving olaparib for prostate cancer for a year and a half. He is being treated at The Royal Marsden. He said: "Over 14 years I've had chemotherapy, radiotherapy, everything they could throw at it. It had spread to my lymph nodes and liver but since I've been on olaparib these tumours have shrunk. I took part in this trial to give something back. I've been on olaparib for 18 months now and can stay on it for as long as it works. I feel very lucky, especially as I feel well."
Find out more about the prostate cancer research undertaken at our Movember Centre of Excellence, a centre that draws together researchers from the ICR, The Royal Marsden, UCL and Imperial College London.
Changes to BRCA and PALB2 genes
Looking at the levels of cancer DNA circulating in the blood, the researchers found that patients who responded to the drug had a median drop in the levels of circulating DNA of 49.6 per cent after only eight weeks of treatment, whereas cancer DNA levels rose by a median of 2.1 per cent in patients who did not respond.
Men whose blood levels of DNA had decreased at eight weeks after treatment survived an average of 17 months, compared with only 10.1 months for men whose cancer DNA levels remained high.
The researchers also performed a detailed examination of the genetic changes that occurred in cancer DNA from patients who had stopped responding to olaparib. They found that cancer cells had acquired new genetic changes that cancelled out the original errors in DNA repair – particularly in the genes BRCA2 and PALB2 – that had made the cancer susceptible to olaparib in the first place.
The research puts into action the central aim of the ICR’s and The Royal Marsden’s research strategy, which is to overcome cancer’s adaptability, evolution and drug resistance.
'Powerful three-in-one test'
Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said: “Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.
“From these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term. We think it could be used to make clinical decisions about whether a PARP inhibitor is working within as little as four to eight weeks of starting therapy.
“Not only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.”
Professor Paul Workman, Chief Executive of the ICR, said: “Blood tests for cancer promise to be truly revolutionary. They are cheap and simple to use, but most importantly, because they aren’t invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing – offering patients the best chance of surviving their disease.
“This test is particularly exciting because it is multi-purpose, designed for use both before and after treatment, and using both the absolute amounts of cancer DNA in the bloodstream and also a readout of the specific mutations within that genetic material. We believe it can usher in a new era of precision medicine for prostate cancer.”
Importance of liquid biopsies
Professor David Cunningham, Director of Clinical Research at The Royal Marsden NHS Foundation Trust, said: “This is another important example where liquid biopsies – a simple blood test as opposed to an invasive tissue biopsy – can be used to direct and improve the treatment of patients with cancer.”
Dr Matthew Hobbs, Deputy Director of Research at Prostate Cancer UK said: “To greatly improve the survival chances of the 47,000 men diagnosed with prostate cancer each year, it’s clear that we need to move away from the current one-size-fits-all approach to much more targeted treatment methods. The results from this study and others like it are crucial as they give an important understanding of the factors that drive certain prostate cancers, or make them vulnerable to specific treatments.
“However, there is still much more to understand before the potentially huge benefits of widespread precision treatment for prostate cancer will reach men in clinics across the UK. That is why Prostate Cancer UK is investing so heavily in this area, including supporting this research released today.”
This article has been republished from materials provided by The Institute of Cancer Research. Note: material may have been edited for length and content. For further information, please contact the cited source.
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., . . . Bono, J. S. (2017). Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery. doi:10.1158/2159-8290.cd-17-0261
"Cell Quake Elastography" Maps Elasticity of Cell ComponentsNews
In somewhat the same way that seismologists use the vibrations of planet Earth to characterize its deep structure, scientists have discovered a way to use vibrations within cells to identify their mechanical properties.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE